See the original post here:
Y-mAbs Presents SADA Platform Preclinical Data and Trial in Progress Posters at the 2024 American Society Hematology (ASH) Annual Meeting
Related Post
- Kraig Biocraft Laboratories Reports Record-Setting Recombinant Spider Silk Production in 2024 - December 11th, 2024
- Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit - December 11th, 2024
- Prelude Therapeutics Presents Preliminary Results of Phase 1 Dose-escalation Study of PRT2527 as Monotherapy and in Combination with Zanubrutinib in... - December 11th, 2024
- AIM’s Clinical Strategy Under Incumbent Board Has Totally Failed - December 11th, 2024
- Scilex Bio, a Controlling Interest of Joint Venture by Scilex Holding Company, Reports Phase 2 Trial for Obesity Currently Enrolling with U.S. Patient... - December 11th, 2024
- Reunion Neuroscience Presented RE104 Phase 1 Data at the 2024 American College of Neuropsychopharmacology (ACNP) 63rd Annual Meeting - December 11th, 2024
- RenovoRx Initiates Patient Enrollment at SCRI Oncology Partners for Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial in Locally Advanced Pancreatic... - December 11th, 2024
- Results from Social Listening Analysis and Survey of People with Narcolepsy Uncover Real-Life Challenges with Twice-Nightly Oxybate Therapy - December 11th, 2024
- Teva Announces New Patient Access Program with Direct Relief to Provide Access to Inhalers for Uninsured Patients - December 11th, 2024
- Hepion Pharmaceuticals, Inc. Announces Termination of Merger Agreement with Pharma Two B Ltd. - December 11th, 2024
- Phathom Pharmaceuticals Submits Citizen Petition to FDA Seeking Correction of Orange Book Listings for VOQUEZNA® (vonoprazan) Tablets - December 11th, 2024
- Angitia Biopharmaceuticals Announces $120 Million Series C Financing - December 11th, 2024
- Genmab to Hold 2024 R&D Update and ASH Data Review Meeting - December 11th, 2024
- Anaptys Announces Phase 2b Trial of ANB032, a BTLA Agonist, Did Not Meet Primary or Secondary Endpoints in Atopic Dermatitis - December 11th, 2024
- Aprea Therapeutics Announces Twice Daily (BID) Dosing of Patients in ABOYA-119 Clinical Trial of ATRN-119 to Potentially Optimize Clinical Outcomes... - December 11th, 2024
- Enlivex Receives Regulatory Authorization for the Initiation of a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis - December 11th, 2024
- New Clinical Trial of eTNS for Pediatric ADHD to Commence at Denmark’s Center for Evidence-Based Psychiatry - December 11th, 2024
- 60 Degrees Pharmaceuticals Expands Tafenoquine Clinical Trial for Babesiosis to Brigham and Women’s Hospital - December 11th, 2024
- Phenocell and Amarna Therapeutics Awarded Eurostars Grant to Assess a Gene Therapy for Dry AMD using a novel 3-dimensional iPSC-derived Retinal Model... - December 11th, 2024
- NurExone Announces Promising Preclinical Results in Restoring Vision After Optic Nerve Damage - December 9th, 2024
- BioAge Labs Announces Discontinuation of STRIDES Phase 2 Clinical Trial Evaluating Azelaprag in Combination with Tirzepatide for the Treatment of... - December 9th, 2024
- Press Release: ASH: rilzabrutinib demonstrated significant patient benefit in the first positive phase 3 study of a BTK inhibitor in ITP - December 9th, 2024
- Athira Pharma Presents Preclinical Data Highlighting Neuroprotective Effects of ATH-1105 in Models of ALS at Motor Neurone Disease Association’s... - December 9th, 2024
- Galapagos Announces Encouraging New Results from Ongoing Phase 1/2 Study of CD19 CAR T-Cell Therapy, GLPG5101, in Patients with Relapsed/Refractory... - December 9th, 2024
- Novel Combination of Pozelimab and Cemdisiran (Poze-Cemdi) Achieved Greater Control of Intravascular Hemolysis in Patients with Paroxysmal Nocturnal... - December 9th, 2024
- Adaptive Biotechnologies Announces New Data at the 66th ASH Annual Meeting Highlighting Advances in MRD Testing with clonoSEQ® and Its Impact on... - December 9th, 2024
- Investigational Epcoritamab (DuoBody® CD3xCD20) Monotherapy Achieves High Overall and Complete Response Rates in Clinical Trial of Patients With... - December 9th, 2024
- Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Demonstrates High Response Rates in Clinical Trial of Patients With Relapsed or... - December 9th, 2024
- Affimed Announces Positive Results Demonstrating Safety and Efficacy of Acimtamig and AlloNK® Combination in Relapsed/Refractory Classical Hodgkin... - December 9th, 2024
- DARZALEX® (daratumumab) subcutaneous formulation shows 51 percent reduction in risk of progression to active multiple myeloma for patients with... - December 9th, 2024
- C4 Therapeutics Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting that Demonstrated Potential to Become... - December 9th, 2024
- Cogent Biosciences Announces Positive Updated Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic... - December 9th, 2024
- Five-year results confirm Roche’s Polivy combination therapy as new standard of care for previously untreated aggressive lymphoma - December 9th, 2024
- Longer-term data for Novartis Scemblix® reinforce superior efficacy with favorable safety and tolerability profile in adults with newly diagnosed CML - December 9th, 2024
- Agios Presents Positive Results from Phase 3 ENERGIZE-T Study of Mitapivat at ASH 2024 and Provides Regulatory Update on Mitapivat - December 9th, 2024
- TECVAYLI®▼ (teclistamab) demonstrates potential as frontline combination therapy for patients with newly diagnosed multiple myeloma - December 9th, 2024
- Zelixir's New Factory to Revolutionize Natural Fragrance Production with ‘AI+Synthetic Biology’ - December 9th, 2024
- Disc Medicine Presents Positive Updated Results from Phase 1b Trial in Patients with Myelofibrosis (MF) and Anemia in an Oral Presentation at the 66th... - December 9th, 2024
- Cidara Therapeutics Completes Enrollment of Phase 2b NAVIGATE Trial Evaluating CD388 for Prevention of Seasonal Influenza - December 5th, 2024
- Grace Therapeutics to Exhibit at the American Society of Health-System Pharmacists Conference - December 5th, 2024
- ARS Pharmaceuticals Announces Planned Launch of neffyinSchools Program to Provide Life-Saving Needle Free Epinephrine to Eligible K-12 Schools at No... - December 5th, 2024
- Windtree Announces Partnership with New Growth Advisors to Leverage Positive Phase 2 Istaroxime Study in Cardiogenic Shock for a Potential Strategic... - December 5th, 2024
- X4 Pharmaceuticals to Present Trial-in-Progress Poster on Phase 3 Study of Mavorixafor in Chronic Neutropenia at 66th ASH Annual Meeting &... - December 5th, 2024
- Adaptive Research Welcomes Western Radiation Oncology to Expand Community Access to Pioneering Cancer Treatment Trials - December 5th, 2024
- Codetta Bio Welcomes Paul McEwan and Mitch Levine as Independent Board Members - December 5th, 2024
- Intelligent Bio Solutions to Host Virtual Fireside Chat on Wednesday, December 11th at 4:30 p.m. ET - December 5th, 2024
- Outlook Therapeutics® Announces NICE Recommendation of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD - December 5th, 2024
- Nephros to Participate in the Benchmark Company Annual Discovery One-on-One Investor Conference on December 11, 2024 in NYC - December 5th, 2024
- BioCardia Announces Positive Consultation with Japan PMDA on CardiAMP Cell Therapy for Ischemic Heart Failure - December 5th, 2024
- Firefly Neuroscience Appoints Current Board Member, Greg Lipschitz, as Executive Chairman - December 5th, 2024
- OmniScience Inc. and INmune Bio Inc. Partner to Accelerate a Phase 2 Alzheimer’s Trial with Vivo, a Novel genAI Clinical Trial Control Tower - December 5th, 2024
- VivaVision Announces Positive Topline Results from Phase 2 Trial of VVN461 for Post-Operative Inflammation Following Cataract Surgery - December 5th, 2024
- Sonnet BioTherapeutics Announces Publication Detailing the Discovery and Development of SON-1010, an Albumin-Binding IL-12 Fusion Protein,... - December 5th, 2024
- Oncocyte Demonstrates Potential for Liquid Biopsy of Brain Tumors in New Study - December 5th, 2024
- Corvus Pharmaceuticals Announces Publication of Biochemistry and Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a... - December 5th, 2024
- FDA Grants Revascor® (Rexlemestrocel-L) Regenerative Medicine Advanced Therapy (RMAT) Designation in Children with Congenital Heart Disease - December 5th, 2024
- Jupiter Neurosciences, Inc. Announces Closing of $11 million Initial Public Offering - December 5th, 2024
- Nxera Pharma Enrolls First Insomnia Patient in its Phase 3 Clinical Trial of Daridorexant in South Korea - December 5th, 2024
- Sana Biotechnology Announces Fast Track Designation for SC291 in Relapsed/Refractory Systemic Lupus Erythematosus - December 3rd, 2024
- Longeveron to Present at the Emerging Growth Virtual Conference on December 5, 2024 - December 3rd, 2024
- OSE Immunotherapeutics Strengthens Leadership and Executive Committee - December 3rd, 2024
- Humacyte to Present at the Piper Sandler 36th Annual Healthcare Conference - December 3rd, 2024
- Foundation Fighting Blindness Partners with University of Colorado Anschutz Medical Campus and Other Leading Institutions to Secure Up to $46 Million... - December 3rd, 2024
- Oncocyte dd-cfDNA Assay Detects Kidney Transplant Rejection 11+ Months Ahead of Standard Protocols, New Study Affirms - December 3rd, 2024
- Vaxart Completes Enrollment of Sentinel Cohort in Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate - December 3rd, 2024
- Optinose to Present at the Piper Sandler 36th Annual Healthcare Conference - December 3rd, 2024
- vTv Therapeutics to Participate in 7th Annual Evercore HealthCONx Conference - December 3rd, 2024
- Certara Showcases 2024 Research Wins With Over 100 Papers Published - December 3rd, 2024
- Capricor Therapeutics to Present at Upcoming Investor Conferences - December 3rd, 2024
- NKGen Biotech Selected as Stalking Horse Bidder for NKMax - December 3rd, 2024
- Jasper Therapeutics Announces First Patient Dosed in Phase 1b/2a ETESIAN Clinical Study of Briquilimab in Asthma - December 3rd, 2024
- Information regarding the total number of voting rights and total number of shares of the Company as of November 30, 2024 - December 3rd, 2024
- Bionomics Reminds Shareholders to Cast their Vote for Re-Domiciliation from Australia to the United States - December 3rd, 2024
- Serina Therapeutics Secures $10 Million Financing to Continue Advancing Lead IND Candidate into Phase 1 Clinical Trial in Advanced Parkinson's Disease... - December 3rd, 2024
- Molecular Templates Announces Receipt of Expected Notification of Deficiency from Nasdaq Related to Delayed filing of Quarterly Report on Form 10-Q... - December 3rd, 2024
- Rakovina Therapeutics Increases Private Placement Offering to $3.0 Million - December 3rd, 2024
- Revascor Improves Survival and Reduces Major Morbidity in High-Risk Ischemic Heart Failure Patients With Inflammation - December 3rd, 2024
- Jupiter Neurosciences, Inc. Announces Pricing of $11 million Initial Public Offering and Listing on Nasdaq - December 3rd, 2024
- Prelude Therapeutics to Participate in Citizens JMP Securities Hematology and Oncology Summit - December 1st, 2024
- KALA BIO to Present at Piper Sandler 36th Annual Healthcare Conference - December 1st, 2024
Recent Comments